Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Furmonertinib 160 mg plus anlotinib in EGFR-mutated NSCLC with brain or leptomeningeal metastases
ChiCTR2500101001Phase 4Not yet recruiting
- Sponsor
- Shandong First Medical University
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of furmonertinib and anlotinib in non-small cell lung cancer (NSCLC), Carcinomatous Meningitis (CM) and brain metastases (2 cohorts), sponsored by Shandong First Medical University. Primary endpoint: Progression-free survival in Cohort 1 and Cohort 2. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
furmonertinibanlotinib
03
Conditions
non-small cell lung cancer (NSCLC)Carcinomatous Meningitis (CM)brain metastases
Beyond the preview
Go deeper on ChiCTR2500101001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500101001.